Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1971 to 1980 of 2706 total matches.

Grepafloxacin--A New Fluoroquinolone

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 1998  (Issue 1019)
Cost* 500 mg on day 1, then 250 mg qd x 4 days Azithromycin − Zithromax (Pfizer) $ 37.31 Cefuroxime ...
Grepafloxacin (Raxar - Glaxo Wellcome), a once-daily oral fluoroquinolone, is now being marketed for treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated gonorrhea, and nongonococcal urethritis and cervicitis.
Med Lett Drugs Ther. 1998 Jan 30;40(1019):17-8 |  Show IntroductionHide Introduction

Creatine and Androstenedione--Two "Dietary Supplements"

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 1998  (Issue 1039)
. The primary food sources for creatine are meat and fish; the usual diet in the USA provides about 1 to 2 ...
Creatine, a natural amino acid derivative, and androstenedione, a testosterone precursor, are marketed as 'dietary supplements' in health food stores and are widely believed to enhance athletic performance. Both have been in the news recently because Mark McGwire, the baseball home-run record-setter, reportedly has said he takes both. Neither has been approved for any indication by the US Food and Drug Administration (FDA).
Med Lett Drugs Ther. 1998 Nov 6;40(1039):105-6 |  Show IntroductionHide Introduction

Modafinil for Narcolepsy

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 1999  (Issue 1049)
in animals without causing agitation. Even though modafinil is not an α 1 -adrenergic agonist, centrally ...
Modafinil (Provigil), a benzhydryl sulfinylacetamide non-amphetamine stimulant that has been used in Europe since 1995, has now been approved by the FDA for treatment of excessive daytime sleepiness associated with narcolepsy.
Med Lett Drugs Ther. 1999 Mar 26;41(1049):30-1 |  Show IntroductionHide Introduction

Quinupristin/Dalfopristin

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 1999  (Issue 1066)
and -resistant Streptococcus pneumoniae (RG Finch, Drugs, 51 suppl 1:31, 1996). It also is active in vitro ...
Quinupristin and dalfopristin, two streptogramin antibacterials marketed in a 30:70 combination as Synercid, have received accelerated approval from the FDA for intravenous treatment of bacteremia and life-threatening infection....
Med Lett Drugs Ther. 1999 Nov 19;41(1066):109-10 |  Show IntroductionHide Introduction

Fluoxetine Sarafem For Premenstrual Dysphoric Disorder

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001  (Issue 1096)
Halbreich et al and EW Freeman et al, Int J Neuropsychopharmacol July 2000; 3 suppl 1:S248 and S241 ...
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) previously sold only as Prozac, is now also marketed as Sarafem for treatment of premenstrual dysphoric disorder (PMDD). Generic fluoxetine is expected to be available sometime this year.
Med Lett Drugs Ther. 2001 Jan 22;43(1096):5-6 |  Show IntroductionHide Introduction

A New Snake Antivenom

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001  (Issue 1107)
is available from Savage Laboratories (1-800-2310206). The cost of 12 vials would be $9,300. Although ...
CroFab, an antigen-binding-fragment (Fab) antivenom of ovine origin, has been approved by the FDA for treatment of North American rattlesnake envenomation.
Med Lett Drugs Ther. 2001 Jun 25;43(1107):55-6 |  Show IntroductionHide Introduction

Zoledronate (Zometa)

   
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001  (Issue 1120)
%) (JP Brown et al, J Bone Miner Res 2001; 16 suppl 1:S218, abstract F353). ADVERSE EFFECTS — Adverse ...
Zoledronic acid (Zometa), a new bisphosphonate, has been approved by the FDA for intravenous (IV) treatment of hypercalcemia of malignancy.
Med Lett Drugs Ther. 2001 Dec 10;43(1120):110-1 |  Show IntroductionHide Introduction

Pegfilgrastim (Neulasta) For Prevention of Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • May 13, 2002  (Issue 1130)
al, Blood 2001; 98 (11 part 1):799a, abstract 3322). No data are available on use of pegfilgrastim ...
Recombinant human granulocyte colony stimulating factor (G-CSF, filgrastim) conjugated to polyethylene glycol (pegfilgrastim, Neulasta - Amgen) has been approved by the FDA for use in neutropenic patients with non-myeloid malignancies who are at high risk for infection. Filgrastim (Neupogen - Amgen) has been available in the US since 1991.
Med Lett Drugs Ther. 2002 May 13;44(1130):44-5 |  Show IntroductionHide Introduction

Anastrozole (Arimidex) vs. Tamoxifen for Treatment of Early Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003  (Issue 1152)
in postmenopausal women. It suppresses serum estrogen to 1%-10% of pre-treatment levels. PHARMACOKINETICS ...
Anastrozole (Arimidex - AstraZeneca, Medical Letter 1996; 38:61), an aromatase inhibitor, has received accelerated approval from the FDA for adjuvant treatment of postmenopausal women with early hormone-receptor-positive breast cancer. The drug was approved for treatment of postmenopausal women with metastatic breast cancer in 1996.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):22-3 |  Show IntroductionHide Introduction

Zingo for Local Analgesia in Children

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008  (Issue 1293)
Publication 1. WT Zempsky et al. A novel needle-free powder lidocaine delivery system for rapid local ...
The FDA has approved the marketing of a new device for delivering lidocaine to the skin of children undergoing a venipuncture or intravenous (IV) line placement. Zingo (Anesiva) is a powder intradermal injection system.
Med Lett Drugs Ther. 2008 Aug 25;50(1293):68 |  Show IntroductionHide Introduction